Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Pain Treatments Move Closer to U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  October 18, 2017

Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…

Filed under:AnalgesicsDrug Updates Tagged with:Knee Osteoarthritis (OA)knee painmeloxicamosteoarthritis (OA)PainPain Medicationpost-surgeryZilretta

Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

Mary Beth Nierengarten  |  October 17, 2017

FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug Updates Tagged with:adalimumabAnkylosing SpondylitisApprovalsbaricitinibBimekizumabBiosimilarsdrug updateefficacyFDAHumiraplaque psoriasisPsoriasisQualityRARheumatoid arthritisrheumatologySafetyTofacitinib

Ethics Forum: A Physician’s Medical Error & the Patient’s Right to Know

Sian Yik Lim, MD, & Marcy B. Bolster, MD  |  October 17, 2017

Case Ms. A is an 82-year-old woman who presented to the rheumatology office for evaluation of osteoporosis. She had been diagnosed with postmenopausal osteoporosis at age 62 after sustaining a right wrist fracture. She was started on alendronate 70 mg weekly and reported medication compliance. At age 79, she sustained an atraumatic right femur fracture….

Filed under:EthicsProfessional Topics Tagged with:disclosureEthicsMedical decision makingmedical errorpatient carepatient satisfactionphysicianphysician-patient communicationrheumatologistrheumatology

Rheumatology Health Professionals

Carol Patton with Ann-Marie Lindstrom  |  October 17, 2017

‘Living’ Pelvis in the Guinness Book of World Records Shashank Akerkar, MD, an ACR fellow and rheumatoid arthritis specialist at the Mumbai Arthritis Clinic and Research Center in India, found a unique way to draw attention to ankylosing spondylitis (AS). He persuaded 425 patients, mostly those suffering from AS or affected by lupus or rheumatoid…

Filed under:Career DevelopmentProfessional TopicsResearch Rheum Tagged with:AwardsCareerProfilepromotionResearchrheumatologistrheumatology health professionals

New Studies Examine Impact of Poverty, Race, Ethnicity in Patients with SLE

Elizabeth Hofheinz, MPH, MEd  |  October 17, 2017

To correctly address a problem, one must have a handle on its nuances—a clear understanding of what is linked and how. And thus far, when it comes to lupus, we haven’t reached the point of understanding those intricacies. Things are heading in the right direction, however, with two new studies that get us much closer…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:DiagnosisDisparitiesimpactincomeinequalityLupuspatient carepovertypregnancyracialResearchRheumatic DiseaserheumatologyrisksocioeconomicStressstudySystemic lupus erythematosus

Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network

Lara C. Pullen, PhD  |  October 17, 2017

CHICAGO—“Why do so many drugs fail in clinical trials?” asked Michael Brenner, MD, chief of rheumatology, immunology and allergy at Brigham and Women’s Hospital in Boston. This question, previously posed by Francis Collins, MD, PhD, director of the National Institutes of Health, prompted a discussion among scientists and stakeholders in the pharmaceutical industry. The conversation…

Filed under:ConditionsMeeting ReportsResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:Accelerating Medicines PartnershipFederation of Clinical Immunology SocietiesFOCIS 2017Lupusmeeting reportsRAResearchRheumatic DiseaseRheumatoid arthritisrheumatologysingle-cell disease"SLESystemic lupus erythematosusTreatment

How Juvenile Idiopathic Arthritis Affects Patients, Families

Catherine I. Morlino  |  October 17, 2017

After having had juvenile idiopathic arthritis (JIA) for 20 years, I had a moment in my journey when I realized something new: “Your arthritis doesn’t just affect you, you know,” my sister said. This statement stopped me in my achy tracks. For two decades, I had been operating under the assumption that JIA was my…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:DiagnosisfamilyJIAJuvenile idiopathic arthritisManagementpatient carequality of lifeRheumatic DiseaserheumatologistrheumatologyTreatment

The ACR Rheumatology Research Workshop Designed to Promote Collaboration, Mentoring Among Investigators

Iris Navarro-Milan, MD, & Jeffrey Sparks, MD, MMSc  |  October 16, 2017

The ACR Rheumatology Research Workshop (RRW) is a two-day meeting designed to promote interactions between early and established investigators to foster collaboration and facilitate career mentoring. The RRW is targeted to rheumatology fellows, junior faculty, medical/graduate students, and residents interested in learning more about how to succeed in a research career for rheumatology. RRW is…

Filed under:Career DevelopmentFrom the CollegeProfessional TopicsResearch Rheum Tagged with:AC&RACR Rheumatology Research WorkshopAmerican College of Rheumatology (ACR)CareercollaborationfacultyFellowsinvestigatormedical studentsMentorResearchrheumatologist

The Legacy of Amyloid: Infiltration Linked to Dementia, Rheumatic Disease

Simon M. Helfgott, MD  |  October 16, 2017

An Unforgettable Story Her name was unforgettable. Not only did we share our given names—Simon and Simone, but her French-Canadian surname was based on this appellation, too. I was the junior resident working on our hospital’s nephrology service when she was admitted for evaluation of progressively worsening kidney disease and an overall failure to thrive….

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:Amyloidosisbraincase reportClinicaldementiaDiagnosismortalityneuronoutcomepatient careplaquerheumatologistrheumatology

U.S. States Plan Suit to Block Trump Obamacare Subsidies Cut

Yasmeen Abutaleb & Dan Levine  |  October 16, 2017

WASHINGTON/SAN FRANCISCO (Reuters)—On Friday, California, New York and others states vowed to sue President Donald Trump’s administration to stop him from scrapping a key component of Obamacare, subsidies to insurers that help millions of low-income people pay medical expenses, even as Trump invited Democratic leaders to negotiate a deal. One day after his administration announced…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Health Insurancehealth insurance paymentsObamacareObamacare collapseTrump administration

  • « Previous Page
  • 1
  • …
  • 173
  • 174
  • 175
  • 176
  • 177
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences